CHEPLAPHARM Reports Record Revenue and Growth in Financial Year 2023

CHEPLAPHARM Arzneimittel GmbH announced a significant financial growth for the year 2023, reporting a 17% increase in revenue, achieving a total of €1,498.4 million compared to €1,279.5 million in 2022. This growth is accompanied by a 14% rise in EBITDA to €780.5 million. The EBITDA margin maintained its industry-leading position at 52%.

The company's strategic acquisitions, including the largest in its history of the Zyprexa® portfolio for €1.3 billion from Eli Lilly, have notably contributed to CHEPLAPHARM’s growth. Additional acquisitions from major pharmaceuticals like Roche, AstraZeneca, and Teva also played key roles. The total investment in acquisitions reached around €1.8 billion for the year.

With the establishment of new affiliates in Japan and Switzerland, CHEPLAPHARM has expanded its international footprint, strengthening its position in essential global markets. The company’s workforce also grew by 24% to 666 employees, bolstering its capability in Greifswald and new locations.

Moreover, CHEPLAPHARM raised over one billion euros through two bond issues in 2023, which facilitated these expansions and acquisitions. This financial maneuver underscores the market's confidence in CHEPLAPHARM's business model and its ongoing growth trajectory.